Loading clinical trials...
Loading clinical trials...
NMDAR Modulation As a Therapeutic Target and Probe of Neural Dysfunction in OCD
Conditions
Interventions
Ketamine
Midazolam
Locations
1
United States
Stanford University
Stanford, California, United States
Start Date
June 1, 2016
Primary Completion Date
June 1, 2026
Completion Date
June 1, 2026
Last Updated
May 31, 2025
NCT06647589
NCT04480918
NCT05623306
NCT07245134
NCT07232823
NCT04131829
Lead Sponsor
Stanford University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions